In vitro selection and analysis of human immunodeficiency virus type 1 resistant to derivatives of beta-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine

Antimicrob Agents Chemother. 2005 Sep;49(9):3930-2. doi: 10.1128/AAC.49.9.3930-3932.2005.

Abstract

Serial passage of human immunodeficiency virus type 1 in MT-2 cells in increasing concentrations of the d- and l-enantiomers of beta-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine (d4FC) resulted in the selection of viral variants with reverse transcriptase substitutions M184I or M184V for l-d4FC and I63L, K65R, K70N, K70E, or R172K for d-d4FC. Phenotypic analysis of site-directed mutants defined the role of these mutations in reducing susceptibility to l- or d-d4FC.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Amino Acid Substitution
  • Anti-HIV Agents / pharmacology*
  • Cell Line
  • Cytidine Triphosphate / analogs & derivatives*
  • Cytidine Triphosphate / pharmacology
  • Drug Resistance, Viral
  • HIV Reverse Transcriptase / genetics
  • HIV Reverse Transcriptase / metabolism
  • HIV-1 / drug effects*
  • HIV-1 / enzymology
  • HIV-1 / genetics
  • Humans
  • Mutagenesis, Site-Directed
  • Mutation / genetics
  • Reverse Transcriptase Inhibitors / pharmacology*
  • Stereoisomerism
  • Structure-Activity Relationship
  • Zalcitabine / analogs & derivatives

Substances

  • Anti-HIV Agents
  • Reverse Transcriptase Inhibitors
  • Cytidine Triphosphate
  • Zalcitabine
  • HIV Reverse Transcriptase
  • dexelvucitabine